There's no doubt. The GLP-1 receptor agonists are effective for weight loss, but is this weight loss at the expense of sarcopenia and increased frailty?
Hear the latest evidence and practical strategies from leading experts.
In this webcast on 13 October, Associate Professor Ralph Audehm and two weight management experts Associate Professor Samantha Hocking and Dr Terri-Lynne South will address the safety of GLP-1 RAs in terms of muscle loss, the role of lifestyle including diet and exercise, and the appropriate monitoring of muscle mass and function.
How do the CPD options work?
- Attend the webcast and earn 2 hrs CPD in the Educational Activities category by attending the webcast lecture and completing the evaluation (RACGP & ACRRM approved)
- Complete the optional post-webcast quiz and earn 0.5 hrs CPD in the Reviewing Performance category (RACGP & ACRRM approved)
- Complete the optional Patient Case Review and earn a further 0.5 hrs CPD in the Reviewing Performance category (RACGP & ACRRM approved)
- Undertake the optional Micro Audit and gain 1 hrs CPD in the Measuring Outcomes category (RACGP & ACRRM approved)
Other professions can self-claim up to 4 hrs CPD.
Attendees will receive Certificate of Attendance about four weeks post-webcast.
Don’t miss out, REGISTER NOW.
Topics include:
Hypertriglyceridaemia – Causes, Assessment & Management of CV Risk
Dr Robert Hungerford
Specialist General Practitioner; GP Supervisor, Marketown Health; Conjoint lecturer, University of Newcastle
Elevated triglycerides are a known marker of residual cardiovascular risk in heart patients already taking optimal secondary prevention. In this talk, GP Robert Hungerford explains the role of triglycerides in atherogenesis and the assessment of residual risk in patients who have had a cardiac event and are already on standard lipid lowering therapy. Importantly, he will also suggest how these elevated triglycerides and this residual risk can be practically and effectively managed in general practice.
The New Dengue Vaccine – What You Need
Dr Deb Mills
Travel Medicine Expert; Medical Director, Dr Deb the Travel Doctor
The new dengue vaccine, Qdenga is now TGA-approved and available for eligible Australian travellers aged four years and over at high risk of contracting the disease. In this talk, travel medicine expert, Dr Deb Mills provides an update on the details of this vaccine including effectiveness, indications and contraindications, side effects and cost. She will also discuss the latest incidence and prevalence of dengue worldwide and how the clinician can assess potential risk for individual travellers and the need for dengue vaccination.
Expert Panel – GLP 1s & Sarcopenia: Fact vs Hype
A/Prof Samantha Hocking
Endocrinologist; Royal Prince Alfred Hospital; Clinical Academic at Charles Perkins Research Centre, University of Sydney; President, National Association of Clinical Obesity Services (NACOS)
&
Dr Terri-Lynne South
General Practitioner and Dietitian; Medical Director, Lifestyle Metabolic
&
A/Prof Ralph Audehm
General Practitioner; Carlton Family Medical, Melbourne; Clinical Associate Professor, University of Melbourne, Department of General Practice
There’s no doubt. The GLP-1 receptor agonists are effective for weight loss, but is this weight loss at the expense of sarcopenia and increased frailty? This is the question discussed by Associate Professor Ralph Audehm and two weight management experts Associate Professor Samantha Hocking and Dr Terri-Lynne South. In this presentation, the safety of GLP-1 RAs in terms of muscle loss, the role of lifestyle including diet and exercise, and the appropriate monitoring of muscle mass and function will all be addressed.
Management of Photoageing
A/Prof Michelle Rodrigues
Every Australian knows the slip, slop, slap campaign, however skin issues related to photoageing continue to be a common presentation in general practice. In this comprehensive talk, dermatologist Associate Professor Michelle Rodrigues will discuss the adverse effects caused by prolonged UV exposure across diverse skin shades, and how these effects are best prevented and treated. She will also suggest how treatment programs can be individualised choosing from the range of currently-available therapies – from topicals to laser and injectables.
Tuesday 13 October 2026
Time:
7pm – 9pm AEDT
6pm – 8pm AEST
6:30pm – 8:30pm ACDT
5:30pm – 7:30pm ACST
4pm – 6pm AWST
